These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Current issues in erythropoietin therapy of renal anemia]. Zakar G Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R; Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [TBL] [Abstract][Full Text] [Related]
8. [Advances in therapy of renal anemia: darbepoetin alfa]. Schaefer R Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460 [No Abstract] [Full Text] [Related]
9. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T; Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489 [TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of erythropoiesis-stimulating agents in CKD. Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621 [TBL] [Abstract][Full Text] [Related]
11. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Foley RN; Curtis BM; Parfrey PS Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988 [TBL] [Abstract][Full Text] [Related]
12. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study]. Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC; Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064 [TBL] [Abstract][Full Text] [Related]
14. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience. Agrawal V; Mukherjee S; Kosuri R; Dumler F Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634 [TBL] [Abstract][Full Text] [Related]
15. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia. Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257 [TBL] [Abstract][Full Text] [Related]
16. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients. Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z; Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials. Sobota JT Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519 [No Abstract] [Full Text] [Related]
19. Evaluation of an anemia algorithm in chronic hemodialysis patients. Nhan J; Jensen L; McMahon A CANNT J; 2007; 17(3):48-58, 62-73; quiz 59-61, 74-6. PubMed ID: 17944348 [TBL] [Abstract][Full Text] [Related]
20. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009. Foley RN; Solid CA; Lamb K Hemodial Int; 2014 Jan; 18(1):24-31. PubMed ID: 24131588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]